Interní Med. 2004; 6(10): 484-488

Poruchy metabolizmu lipidů a hypolipidemická léčba u nefrologických nemocných

prof. MUDr. Vladimír Teplan DrSc, MUDr. Dalibor Lecian
Klinika nefrologie TC IKEM a Subkatedra nefrologie IPVZ

Keywords: hyperlipidemia, renal insufficiency, statins, fibrates.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Teplan V, Lecian D. Poruchy metabolizmu lipidů a hypolipidemická léčba u nefrologických nemocných. Interní Med. 2004;6(10):484-488.

Porucha metabolizmu lipidů je velmi častá u nemocných s chorobami ledvin. Je zvláště výrazná u nemocných v chronické renální insuficienci, v dialyzačním programu, po transplantaci ledviny a u nemocných s nefrotickým syndromem.

Hyperlipidemie je spojena se zvýšeným rizikem aterosklerotických změn i akcelerovanou progresí chronické renální insuficience a chronické rejekce po transplantaci ledviny.

Účinná léčba statiny významně ovlivňuje prognózu nemocných.

Lipid metabolism disorders and its treatment in chronic renal patients

Disorders in lipid metabolism are very frequently found in chronic renal patients mainly in chronic renal insufficiency, in dialysis and transplantation and in nephrotic syndrom.

Hyperlipidemia can increase the risk of atherosclerosic changes and acclerated progression of chronic renal insufficiency and chronic transplant rejection.

Effective treatment with statins influences prognosis of the patients.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bianchi S, Bigazzi R, Caiazza A, Campese VMA. Controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am j Kidney Dis. 2003; 41: 565-570. Go to original source... Go to PubMed...
    2. Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000; 35: 549-555. Go to original source... Go to PubMed...
    3. Fried FL, Orchand JT, Kasiske LB. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney International, 2001; 59: 260-269. Go to original source... Go to PubMed...
    4. Gueler F, Rong S, Park JK, Fiebeler A, Manne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol, 2002; 13: 2288-2298. Go to original source... Go to PubMed...
    5. Guijarro C, Kasiske BL, Kim Y, O´Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. Am J Kidney Dis., 1995; 26 (1): 152-161. Go to original source... Go to PubMed...
    6. Holdaas H, Jardine AG, Wheeler DC, Brekke IB, Conlon PJ, Fellstrom B, Hammad A, Holme I, Isoniemi H, Moore R, Rowe PA, Sweny P, Talbot DA, Wadstrom J, Ostraat O. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int. Nov, 2001; 60 (5): 1990-1997. Go to original source... Go to PubMed...
    7. Jiang J, Sun CW, Alonso-Galicia M, Roman RJ. Lovastatin reduces renal vascular reactivity in spontaneously hypertensive rats. Am J Hypertens. 1998; 11: 1222-1231. Go to original source... Go to PubMed...
    8. Kasiske BL, Heim-Duthov KL, Winter GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72 (2): 223-227. Go to original source... Go to PubMed...
    9. Kasiske, et al. Clinical Practice Guidelines for managing dyslipidemias in chronic kidney disease. Am. J. Kidney, Dis 2003; 41/4, Supl. 3. Go to original source... Go to PubMed...
    10. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. New Engl. J. Med. 1995; 333: 621-627. Go to original source... Go to PubMed...
    11. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6: 1004-1010. Go to original source... Go to PubMed...
    12. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000; 6: 1399-1402. Go to original source... Go to PubMed...
    13. Lee TM, Su SF, Tsai CH H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 2002; 40: 67-73. Go to original source... Go to PubMed...
    14. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002; 54: 395-399. Go to original source... Go to PubMed...
    15. Teplan V. Metabolizmus a ledviny. Grada Avicenum 2000: 412 s.
    16. Terada Y, Inoshita S, Nakashima O, Yamada T, Kuwahara M, Sasaki S, Marumo F. Lovastatin inhibits mesangial cell proliferation via p27Kip1. J Am Soc Nephrol. 1998; 9: 2235-2243. Go to original source... Go to PubMed...
    17. Usui H, Shikata K, Matsuda M, Okada S, Ogava D, Yamashita T, Hida K, Satoh M, Wada J, Makino H. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant. 2003; 18: 265-272. Go to original source... Go to PubMed...
    18. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745. Go to original source... Go to PubMed...
    19. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C, Cottens S, Takada Y, Hommel U. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2002; 7: 687-692. Go to original source... Go to PubMed...
    20. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. Circulation 1997; 96: 1398-1402. Go to original source... Go to PubMed...
    21. Widimsky J. Léčba dyslipidemie. Triton 2002: 190 s.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.